Licensed Seasonal Influenza Vaccine

Phase 1Vaccine

Licensed Seasonal Influenza Vaccine is one of 2 therapeutic programs targeting Influenza, Human+COVID-19. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Influenza, Human+covid-19Active, not recruiting

Influenza, Human+covid-19Phase 1

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Influenza, Human+covid-19

#DrugCompanyPhaseTrials

Licensed COVID-19 Vaccine

GSK

Phase 1

1 2

Licensed Seasonal Influenza Vaccine

GSK

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Influenza, Human+covid-19

NCT07464314

Clinical

Trials by Indication[1]

Influenza, Human+COVID-191 trial

A Phase 1, Observer-Blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of an Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

Recruiting· GSK logo

GSK·Phase 1·NCT07464314·225 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Licensed Seasonal Influenza Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Licensed Seasonal Influenza Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine
Highest Phase: Phase 1[1]
Company: GSK

Licensed Seasonal Influenza Vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Influenza, Human+COVID-191 trial

References

Drug Info

Quick Facts

Related News